We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

65 hedge funds and large institutions have $36.7M invested in Matinas BioPharma in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 12

7% more capital invested

Capital invested by funds: $34.4M → $36.7M (+$2.31M)

0.1% less ownership

Funds ownership: 0.58% → 0.48% (-0.1%)

4% less funds holding

Funds holding: 68 → 65 (-3)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

Holders
65
Holders Change
-3
Holders Change %
-4.41%
% of All Funds
1.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
16
Reduced
12
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$467K
2
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
+$460K
3
BCM
Bridgeway Capital Management
Texas
+$288K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$225K
5
California Public Employees Retirement System
California Public Employees Retirement System
California
+$207K

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$5.04M
2
BBA
Baker Bros. Advisors
New York
-$1.27M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$775K
4
Renaissance Technologies
Renaissance Technologies
New York
-$581K
5
Morgan Stanley
Morgan Stanley
New York
-$542K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAG
26
Crestwood Advisors Group
Massachusetts
$110K – – –
PAG
27
Private Advisor Group
New Jersey
$107K +$23.6K +615 +29%
State Street
28
State Street
Massachusetts
$98K – – –
Citadel Advisors
29
Citadel Advisors
Florida
$90K +$89.6K +2,337 New
UBS Group
30
UBS Group
Switzerland
$85K +$78.3K +2,042 +1,238%
WG
31
Winton Group
United Kingdom
$78K -$6.02K -157 -7%
BJL
32
Brighton Jones LLC
Washington
$70K – – –
CDH
33
Charles D. Hyman
$62K – – –
Hudson Bay Capital Management
34
Hudson Bay Capital Management
Connecticut
$57K +$57.5K +1,500 New
MA
35
MONECO Advisors
Connecticut
$46K +$46K +1,200 New
Russell Investments Group
36
Russell Investments Group
United Kingdom
$40K +$39.8K +1,038 New
JP Morgan Chase
37
JP Morgan Chase
New York
$35K – – –
Charles Schwab
38
Charles Schwab
California
$28K – – –
Stifel Financial
39
Stifel Financial
Missouri
$27K -$3.18K -83 -11%
AWA
40
Arete Wealth Advisors
Illinois
$23K – – –
CWM
41
CCG Wealth Management
California
$23K – – –
Commonwealth Equity Services
42
Commonwealth Equity Services
Massachusetts
$20K – – –
ECM
43
ExodusPoint Capital Management
New York
$16K -$232K -6,061 -93%
DAS
44
Dynamic Advisor Solutions
Arizona
$16K – – –
Janney Montgomery Scott
45
Janney Montgomery Scott
Pennsylvania
$15K -$3.07K -80 -17%
RC
46
RegentAtlantic Capital
New Jersey
$15K – – –
GCP
47
GSA Capital Partners
United Kingdom
$15K +$14.7K +384 New
NRS
48
Neville Rodie & Shaw
New York
$14K – – –
SBWIC
49
Schaper Benz & Wise Investment Counsel
Wisconsin
$11K – – –
SPC
50
Sigma Planning Corp
Michigan
$10K +$499 +13 +5%
1
2
3

MTNB Hedge Fund Activity: Q2 2020 in Review

65 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2020, worth a combined $36.7M — up 6.7% from $34.4M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of MTNB and 8 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 16 added.

The largest buyer was Two Sigma Investments, adding an estimated $467K. The largest seller was Victory Capital Management, cutting an estimated $5.04M.

  • 65 institutional investors held Matinas BioPharma (MTNB) as of Q2 2020, down from 68 in Q1 2020.
  • Funds reported $36.7M of Matinas BioPharma stock for Q2 2020, up 6.7% quarter-over-quarter.
  • 8 funds opened new Matinas BioPharma positions in Q2 2020 and 11 closed out, a net change of -3 holders.
  • The largest Matinas BioPharma buyer in Q2 2020 was Two Sigma Investments, an estimated $467K added.
  • The largest Matinas BioPharma seller in Q2 2020 was Victory Capital Management, an estimated $5.04M sold.

Based on aggregated 13F filings for Q2 2020.